Frequently Asked Questions about Serina Therapeutics, Inc. (SER)

Name: Serina Therapeutics, Inc. (SER) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Serina Therapeutics, Inc. (SER) do?

Accepted Answer

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's dis...

Question 2

Is Serina Therapeutics, Inc. (SER) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of SER reveals an Altman Z-Score of -20.98 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if SER fits their risk profile.

Question 3

What is the current P/E ratio for SER?

Accepted Answer

As of the latest trading session, Serina Therapeutics, Inc. (SER) has a trailing P/E ratio of -1.10.

Question 4

Who is the CEO of Serina Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Serina Therapeutics, Inc. is Steven A. Ledger.

Question 5

What was SER's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Serina Therapeutics, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does SER pay a dividend?

Accepted Answer

Serina Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does SER have?

Accepted Answer

In its latest reporting period, Serina Therapeutics, Inc. generated $-0.02B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Serina Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Serina Therapeutics, Inc. (SER) is currently -570.09.

Question 9

What is the Price-to-Sales (P/S) ratio of SER?

Accepted Answer

Based on trailing twelve-month data, Serina Therapeutics, Inc. (SER) trades at a Price-to-Sales (P/S) ratio of 159.23.

Question 10

What is Serina Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Serina Therapeutics, Inc. (SER) has a Return on Equity (ROE) of -1468.20%, representing its profitability relative to shareholder equity.